Charles River Laboratories International Inc. (NYSE:CRL) reached a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $87.98 and last traded at $87.98, with a volume of 143,927 shares. The stock had previously closed at $86.35.

CRL has been the topic of several analyst reports. Barclays PLC raised their price objective on Charles River Laboratories International from $60.00 to $65.00 and gave the stock an “underweight” rating in a report on Friday, May 20th. Zacks Investment Research raised Charles River Laboratories International from a “hold” rating to a “buy” rating and set a $92.00 target price on the stock in a research report on Friday, June 17th. KeyCorp reaffirmed a “hold” rating and issued a $77.00 target price on shares of Charles River Laboratories International in a research report on Sunday, May 22nd. Gabelli started coverage on Charles River Laboratories International in a research report on Tuesday, April 26th. They issued a “buy” rating and a $96.00 target price on the stock. Finally, Credit Suisse Group AG started coverage on Charles River Laboratories International in a research report on Monday, June 20th. They issued a “neutral” rating and a $84.00 target price on the stock. Two analysts have rated the stock with a sell rating, five have given a hold rating and six have given a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $83.27.

The firm has a market cap of $4.14 billion and a price-to-earnings ratio of 27.01. The stock has a 50 day moving average price of $83.99 and a 200 day moving average price of $79.11.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings data on Wednesday, May 4th. The company reported $0.98 EPS for the quarter, beating the Zacks’ consensus estimate of $0.90 by $0.08. The firm earned $354.90 million during the quarter, compared to the consensus estimate of $354.92 million. During the same period in the prior year, the company posted $0.79 earnings per share. The company’s revenue for the quarter was up 10.8% compared to the same quarter last year. On average, equities research analysts predict that Charles River Laboratories International Inc. will post $4.39 EPS for the current year.

In related news, CAO John J. Crowley sold 1,913 shares of the business’s stock in a transaction on Tuesday, May 24th. The shares were sold at an average price of $85.00, for a total transaction of $162,605.00. Following the transaction, the chief accounting officer now owns 6,883 shares in the company, valued at approximately $585,055. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Richard F. Wallman sold 2,720 shares of the business’s stock in a transaction on Friday, May 6th. The shares were sold at an average price of $81.00, for a total transaction of $220,320.00. Following the transaction, the director now owns 15,430 shares in the company, valued at approximately $1,249,830. The disclosure for this sale can be found here.

Several hedge funds and institutional investors recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its position in Charles River Laboratories International by 2.4% in the fourth quarter. Vanguard Group Inc. now owns 4,182,744 shares of the company’s stock worth $336,251,000 after buying an additional 97,314 shares during the last quarter. Liberty Mutual Group Asset Management Inc. increased its position in Charles River Laboratories International by 51.3% in the fourth quarter. Liberty Mutual Group Asset Management Inc. now owns 30,157 shares of the company’s stock worth $2,424,000 after buying an additional 10,231 shares during the last quarter. BOKF NA increased its position in Charles River Laboratories International by 85.6% in the fourth quarter. BOKF NA now owns 23,179 shares of the company’s stock worth $1,863,000 after buying an additional 10,691 shares during the last quarter. Mutual of America Capital Management LLC increased its position in Charles River Laboratories International by 0.5% in the fourth quarter. Mutual of America Capital Management LLC now owns 31,278 shares of the company’s stock worth $2,514,000 after buying an additional 164 shares during the last quarter. Finally, Morgan Stanley increased its position in Charles River Laboratories International by 23.3% in the fourth quarter. Morgan Stanley now owns 293,248 shares of the company’s stock worth $23,573,000 after buying an additional 55,393 shares during the last quarter.

Charles River Laboratories International, Inc is a full service, early-stage contract research company. The Company is engaged in the business of providing the research models required in research and development of new drugs, devices and therapies. The Company operates through three segments: Research Models and Services (RMS), which consists of Research Models and Research Model Services; Discovery and Safety Assessment (DSA), which offers discovery and safety assessment services, both regulated and non-regulated, in which it includes both in vivo and in vitro studies, and Manufacturing Support (Manufacturing), which includes Microbial Solutions, Biologics Testing Solutions and Avian Vaccine Services.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.